Drugs / Lacidofil
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01853124 | Nov 2013 → May 2017 | gastroenteritis | Dr. Stephen Freedman | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT06990568 | Jun 2025 → May 2026 overdue | diarrheal disease, pneumonia | National Health Insurance Service Ilsan Hospital | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02335632 Comparator | Dec 2012 → Feb 2015 | alcoholic liver disease | Chuncheon Sacred Heart Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lacidofil | “Lacidofil®” NCT02335632 ↗ |
| Modality | Other / unclassified | “administration of a probiotic agent (Lacidofil)” NCT01853124 ↗ |
| Route | Oral | “taken within 30 minutes of food/drink” NCT01853124 ↗ |